Naringin in cholestatic liver ischemia-reperfusion injury

ABSTRACT Purpose: To evaluate the potential protective effects of naringin on liver by oxidative parameters and signal peptide-CUB-EGF-like domain-containing protein (SCUBE)-1 and 2 in an experimental cholestatic liver ischemia reperfusion (IR) model. Methods: Twenty-four female rats were divided...

Full description

Saved in:
Bibliographic Details
Main Authors: Arif Aslaner, Kemal Eyvaz, Erhan Aydemir, Şenay Yıldırım, Kübra Kılıç Kartal, Hamit Yaşar Ellidağ, Uğur Doğan
Format: Article
Language:English
Published: Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia 2025-06-01
Series:Acta Cirúrgica Brasileira
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-86502025000100225&lng=en&tlng=en
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850119651042787328
author Arif Aslaner
Kemal Eyvaz
Erhan Aydemir
Şenay Yıldırım
Kübra Kılıç Kartal
Hamit Yaşar Ellidağ
Uğur Doğan
author_facet Arif Aslaner
Kemal Eyvaz
Erhan Aydemir
Şenay Yıldırım
Kübra Kılıç Kartal
Hamit Yaşar Ellidağ
Uğur Doğan
author_sort Arif Aslaner
collection DOAJ
description ABSTRACT Purpose: To evaluate the potential protective effects of naringin on liver by oxidative parameters and signal peptide-CUB-EGF-like domain-containing protein (SCUBE)-1 and 2 in an experimental cholestatic liver ischemia reperfusion (IR) model. Methods: Twenty-four female rats were divided into three groups; sham, control, and treatment. Groups 2 and 3 underwent bile duct ligation, and one week later, 45 min of ischemia and 1 hour of relaparotomy and reperfusion were performed. To the treatment group, naringin was administered through relaparotomy. Liver tissue and blood samples were taken. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin (TBIL), direct bilirubin (DBIL), ischemia-modified albumin (IMA), SCUBE-1, SCUBE-2, total antioxidant status (TAS), and total oxidant status (TOS) levels were also examined. Results: Serum ALT, AST, ALP, TBIL, DBIL, and IMA levels were higher in groups 2 and 3. There was no significant difference in terms of SCUBE-1 and 2 levels (p > 0.05). TAS was the highest in group 3, and TOS was the highest in group 2 and lower in group 3. In histopathological analysis, all parameters were statistically significant between group 3 and the other groups (p < 0.05). Conclusion: Naringin has promising results in the treatment of experimental IR injury in cholestatic liver due to its antioxidant effects. We think that it can be used in clinical studies after more comprehensive studies investigating its effects on IR damage in cholestatic liver.
format Article
id doaj-art-cc8edef2e77d475c8a86f2af6980c3c9
institution OA Journals
issn 1678-2674
language English
publishDate 2025-06-01
publisher Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia
record_format Article
series Acta Cirúrgica Brasileira
spelling doaj-art-cc8edef2e77d475c8a86f2af6980c3c92025-08-20T02:35:35ZengSociedade Brasileira para o Desenvolvimento da Pesquisa em CirurgiaActa Cirúrgica Brasileira1678-26742025-06-014010.1590/acb404225Naringin in cholestatic liver ischemia-reperfusion injuryArif Aslanerhttps://orcid.org/0000-0001-7346-6977Kemal Eyvazhttps://orcid.org/0000-0002-7410-107XErhan Aydemirhttps://orcid.org/0000-0002-9586-819XŞenay Yıldırımhttps://orcid.org/0000-0002-1457-7957Kübra Kılıç Kartalhttps://orcid.org/0009-0006-4490-2630Hamit Yaşar Ellidağhttps://orcid.org/0000-0002-7511-2547Uğur Doğanhttps://orcid.org/0000-0001-8097-3168ABSTRACT Purpose: To evaluate the potential protective effects of naringin on liver by oxidative parameters and signal peptide-CUB-EGF-like domain-containing protein (SCUBE)-1 and 2 in an experimental cholestatic liver ischemia reperfusion (IR) model. Methods: Twenty-four female rats were divided into three groups; sham, control, and treatment. Groups 2 and 3 underwent bile duct ligation, and one week later, 45 min of ischemia and 1 hour of relaparotomy and reperfusion were performed. To the treatment group, naringin was administered through relaparotomy. Liver tissue and blood samples were taken. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin (TBIL), direct bilirubin (DBIL), ischemia-modified albumin (IMA), SCUBE-1, SCUBE-2, total antioxidant status (TAS), and total oxidant status (TOS) levels were also examined. Results: Serum ALT, AST, ALP, TBIL, DBIL, and IMA levels were higher in groups 2 and 3. There was no significant difference in terms of SCUBE-1 and 2 levels (p > 0.05). TAS was the highest in group 3, and TOS was the highest in group 2 and lower in group 3. In histopathological analysis, all parameters were statistically significant between group 3 and the other groups (p < 0.05). Conclusion: Naringin has promising results in the treatment of experimental IR injury in cholestatic liver due to its antioxidant effects. We think that it can be used in clinical studies after more comprehensive studies investigating its effects on IR damage in cholestatic liver.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-86502025000100225&lng=en&tlng=enLiverCholestasisIschemiaPerfusion
spellingShingle Arif Aslaner
Kemal Eyvaz
Erhan Aydemir
Şenay Yıldırım
Kübra Kılıç Kartal
Hamit Yaşar Ellidağ
Uğur Doğan
Naringin in cholestatic liver ischemia-reperfusion injury
Acta Cirúrgica Brasileira
Liver
Cholestasis
Ischemia
Perfusion
title Naringin in cholestatic liver ischemia-reperfusion injury
title_full Naringin in cholestatic liver ischemia-reperfusion injury
title_fullStr Naringin in cholestatic liver ischemia-reperfusion injury
title_full_unstemmed Naringin in cholestatic liver ischemia-reperfusion injury
title_short Naringin in cholestatic liver ischemia-reperfusion injury
title_sort naringin in cholestatic liver ischemia reperfusion injury
topic Liver
Cholestasis
Ischemia
Perfusion
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-86502025000100225&lng=en&tlng=en
work_keys_str_mv AT arifaslaner naringinincholestaticliverischemiareperfusioninjury
AT kemaleyvaz naringinincholestaticliverischemiareperfusioninjury
AT erhanaydemir naringinincholestaticliverischemiareperfusioninjury
AT senayyıldırım naringinincholestaticliverischemiareperfusioninjury
AT kubrakılıckartal naringinincholestaticliverischemiareperfusioninjury
AT hamityasarellidag naringinincholestaticliverischemiareperfusioninjury
AT ugurdogan naringinincholestaticliverischemiareperfusioninjury